AI's early, uneven impact on clinical trials sparks surprise

The pharmaceutical industry is beginning to see artificial intelligence applied to clinical trial processes, though adoption is occurring in fits and starts.

Early uses of AI are emerging in areas that may not be obvious, offering unexpected ways to streamline trial design, patient recruitment, and data analysis.

While the technology holds promise to transform the speed and efficiency of drug development, its current impact remains modest and uneven across the sector.

Stakeholders are advised to start with small, well-defined AI projects to build experience before scaling broader applications.